O	0	6	Effect
O	7	9	of
O	10	11	a
B-intervention	12	17	Scalp
I-intervention	18	25	Cooling
I-intervention	26	32	Device
O	33	35	on
B-condition	36	44	Alopecia
O	45	47	in
B-eligibility	48	53	Women
I-eligibility	54	64	Undergoing
I-eligibility	65	77	Chemotherapy
I-eligibility	78	81	for
I-eligibility	82	88	Breast
I-eligibility	89	95	Cancer
O	95	96	:
O	97	100	The
O	101	106	SCALP
O	107	117	Randomized
O	118	126	Clinical
O	127	132	Trial
O	132	133	.

O	134	146	Chemotherapy
O	147	150	may
O	151	157	induce
O	158	166	alopecia
O	166	167	.

O	168	176	Although
O	177	182	scalp
O	183	190	cooling
O	191	198	devices
O	199	203	have
O	204	208	been
O	209	213	used
O	214	216	to
O	217	224	prevent
O	225	229	this
O	230	238	alopecia
O	238	239	,
O	240	248	efficacy
O	249	252	has
O	253	256	not
O	257	261	been
O	262	270	assessed
O	271	273	in
O	274	275	a
O	276	286	randomized
O	287	295	clinical
O	296	301	trial
O	301	302	.

O	303	305	To
O	306	312	assess
O	313	320	whether
O	321	322	a
O	323	328	scalp
O	329	336	cooling
O	337	343	device
O	344	346	is
O	347	356	effective
O	357	359	at
O	360	368	reducing
O	369	381	chemotherapy
O	381	382	-
O	382	389	induced
O	390	398	alopecia
O	399	402	and
O	403	405	to
O	406	412	assess
O	413	420	adverse
O	421	430	treatment
O	431	438	effects
O	438	439	.

O	440	451	Multicenter
O	452	462	randomized
O	463	471	clinical
O	472	477	trial
O	478	480	of
O	481	486	women
O	487	491	with
O	492	498	breast
O	499	505	cancer
O	506	516	undergoing
O	517	529	chemotherapy
O	529	530	.

O	531	539	Patients
O	540	544	were
O	545	553	enrolled
O	554	558	from
O	559	567	December
O	568	569	9
O	569	570	,
O	571	575	2013
O	575	576	,
O	577	579	to
O	580	589	September
O	590	592	30
O	592	593	,
O	594	598	2016
O	598	599	.

O	600	603	One
O	604	611	interim
O	612	620	analysis
O	621	624	was
O	625	632	planned
O	633	635	to
O	636	641	allow
O	642	645	the
O	646	651	study
O	652	654	to
O	655	659	stop
O	660	665	early
O	666	669	for
O	670	678	efficacy
O	678	679	.

O	680	684	Data
O	685	693	reported
O	694	697	are
O	698	702	from
O	703	706	the
O	707	714	interim
O	715	723	analysis
O	723	724	.

O	725	729	This
O	730	735	study
O	736	739	was
O	740	749	conducted
O	750	752	at
O	753	754	7
O	755	760	sites
O	761	763	in
O	764	767	the
B-location	768	774	United
I-location	775	781	States
O	781	782	,
O	783	786	and
B-total-participants	787	790	182
B-eligibility	791	796	women
I-eligibility	797	801	with
I-eligibility	802	808	breast
I-eligibility	809	815	cancer
I-eligibility	816	825	requiring
I-eligibility	826	838	chemotherapy
O	839	843	were
O	844	852	enrolled
O	853	856	and
O	857	867	randomized
O	867	868	.

O	869	881	Participants
O	882	886	were
O	887	897	randomized
O	898	900	to
O	901	906	scalp
O	907	914	cooling
O	915	916	(
O	916	917	n
O	918	919	=
B-intervention-participants	920	923	119
O	923	924	)
O	925	927	or
B-control	928	935	control
O	936	937	(
O	937	938	n
O	939	940	=
B-control-participants	941	943	63
O	943	944	)
O	944	945	.

O	946	951	Scalp
O	952	959	cooling
O	960	963	was
O	964	968	done
O	969	974	using
O	975	976	a
O	977	982	scalp
O	983	990	cooling
O	991	997	device
O	997	998	.

O	999	1002	The
O	1003	1010	primary
O	1011	1019	efficacy
O	1020	1023	end
O	1024	1030	points
O	1031	1035	were
B-outcome-Measure	1036	1046	successful
I-outcome-Measure	1047	1051	hair
I-outcome-Measure	1052	1064	preservation
O	1065	1073	assessed
O	1074	1079	using
O	1080	1083	the
O	1084	1090	Common
O	1091	1102	Terminology
O	1103	1111	Criteria
O	1112	1115	for
O	1116	1123	Adverse
O	1124	1130	Events
O	1131	1138	version
O	1139	1140	4
O	1140	1141	.
O	1141	1142	0
O	1143	1148	scale
O	1149	1150	(
O	1150	1155	grade
O	1156	1157	0
O	1158	1159	[
O	1159	1161	no
O	1162	1166	hair
O	1167	1171	loss
O	1171	1172	]
O	1173	1175	or
O	1176	1181	grade
O	1182	1183	1
O	1184	1185	[
O	1185	1186	<
O	1186	1188	50
O	1188	1189	%
O	1190	1194	hair
O	1195	1199	loss
O	1200	1203	not
O	1204	1213	requiring
O	1214	1215	a
O	1216	1219	wig
O	1219	1220	]
O	1221	1225	were
O	1226	1236	considered
O	1237	1239	to
O	1240	1244	have
O	1245	1249	hair
O	1250	1262	preservation
O	1262	1263	)
O	1264	1266	at
O	1267	1270	the
O	1271	1274	end
O	1275	1277	of
O	1278	1279	4
O	1280	1286	cycles
O	1287	1289	of
O	1290	1302	chemotherapy
O	1303	1305	by
O	1306	1307	a
O	1308	1317	clinician
O	1318	1325	unaware
O	1326	1328	of
O	1329	1338	treatment
O	1339	1349	assignment
O	1349	1350	,
O	1351	1354	and
O	1355	1361	device
O	1362	1368	safety
O	1368	1369	.

O	1370	1379	Secondary
O	1380	1383	end
O	1384	1390	points
O	1391	1399	included
B-outcome-Measure	1400	1403	wig
I-outcome-Measure	1404	1407	use
O	1408	1411	and
O	1412	1418	scores
O	1419	1421	on
O	1422	1425	the
O	1426	1434	European
O	1435	1447	Organisation
O	1448	1451	for
O	1452	1460	Research
O	1461	1464	and
O	1465	1474	Treatment
O	1475	1477	of
O	1478	1484	Cancer
B-outcome-Measure	1485	1492	Quality
I-outcome-Measure	1493	1495	of
I-outcome-Measure	1496	1500	Life
O	1501	1514	Questionnaire
O	1514	1515	-
O	1515	1519	Core
O	1520	1522	30
O	1522	1523	,
B-outcome-Measure	1524	1532	Hospital
I-outcome-Measure	1533	1540	Anxiety
I-outcome-Measure	1541	1544	and
I-outcome-Measure	1545	1555	Depression
I-outcome-Measure	1556	1561	Scale
O	1561	1562	,
O	1563	1566	and
O	1567	1568	a
B-outcome-Measure	1569	1576	summary
I-outcome-Measure	1577	1582	scale
I-outcome-Measure	1583	1585	of
I-outcome-Measure	1586	1589	the
I-outcome-Measure	1590	1594	Body
I-outcome-Measure	1595	1600	Image
I-outcome-Measure	1601	1606	Scale
O	1606	1607	.

O	1608	1610	At
O	1611	1614	the
O	1615	1619	time
O	1620	1622	of
O	1623	1626	the
O	1627	1634	interim
O	1635	1643	analysis
O	1643	1644	,
B-total-participants	1645	1648	142
O	1649	1661	participants
O	1662	1666	were
O	1667	1676	evaluable
O	1676	1677	.

O	1678	1681	The
O	1682	1686	mean
O	1687	1688	(
O	1688	1690	SD
O	1690	1691	)
O	1692	1695	age
O	1696	1698	of
O	1699	1702	the
O	1703	1711	patients
O	1712	1715	was
B-age	1716	1718	52
I-age	1718	1719	.
I-age	1719	1720	6
I-age	1721	1722	(
I-age	1722	1724	10
I-age	1724	1725	.
I-age	1725	1726	1
I-age	1726	1727	)
I-age	1728	1733	years
O	1733	1734	;
O	1735	1737	36
O	1737	1738	%
O	1739	1740	(
O	1740	1741	n
O	1742	1743	=
O	1744	1746	51
O	1746	1747	)
O	1748	1756	received
O	1757	1770	anthracycline
O	1770	1771	-
O	1771	1776	based
O	1777	1789	chemotherapy
O	1790	1793	and
O	1794	1796	64
O	1796	1797	%
O	1798	1799	(
O	1799	1800	n
O	1801	1802	=
O	1803	1805	91
O	1805	1806	)
O	1807	1815	received
O	1816	1822	taxane
O	1822	1823	-
O	1823	1828	based
O	1829	1841	chemotherapy
O	1841	1842	.

B-outcome	1843	1853	Successful
I-outcome	1854	1858	hair
I-outcome	1859	1871	preservation
O	1872	1875	was
O	1876	1881	found
O	1882	1884	in
B-iv-bin-abs	1885	1887	48
O	1888	1890	of
B-intervention-participants	1891	1893	95
O	1894	1899	women
O	1900	1904	with
O	1905	1912	cooling
O	1913	1914	(
B-iv-bin-percent	1914	1916	50
I-iv-bin-percent	1916	1917	.
I-iv-bin-percent	1917	1918	5
I-iv-bin-percent	1918	1919	%
O	1919	1920	;
O	1921	1923	95
O	1923	1924	%
O	1925	1927	CI
O	1927	1928	,
O	1929	1931	40
O	1931	1932	.
O	1932	1933	7
O	1933	1934	%
O	1934	1935	-
O	1935	1937	60
O	1937	1938	.
O	1938	1939	4
O	1939	1940	%
O	1940	1941	)
O	1942	1950	compared
O	1951	1955	with
B-cv-bin-abs	1956	1957	0
O	1958	1960	of
B-control-participants	1961	1963	47
O	1964	1969	women
O	1970	1972	in
O	1973	1976	the
O	1977	1984	control
O	1985	1990	group
O	1991	1992	(
B-cv-bin-percent	1992	1993	0
I-cv-bin-percent	1993	1994	%
O	1994	1995	;
O	1996	1998	95
O	1998	1999	%
O	2000	2002	CI
O	2002	2003	,
O	2004	2005	0
O	2005	2006	%
O	2006	2007	-
O	2007	2008	7
O	2008	2009	.
O	2009	2010	6
O	2010	2011	%
O	2011	2012	)
O	2013	2014	(
O	2014	2021	success
O	2022	2026	rate
O	2027	2037	difference
O	2037	2038	,
O	2039	2041	50
O	2041	2042	.
O	2042	2043	5
O	2043	2044	%
O	2044	2045	;
O	2046	2048	95
O	2048	2049	%
O	2050	2052	CI
O	2052	2053	,
O	2054	2056	40
O	2056	2057	.
O	2057	2058	5
O	2058	2059	%
O	2059	2060	-
O	2060	2062	60
O	2062	2063	.
O	2063	2064	6
O	2064	2065	%
O	2065	2066	)
O	2066	2067	.

O	2068	2075	Because
O	2076	2079	the
O	2080	2081	1
O	2081	2082	-
O	2082	2088	tailed
O	2089	2090	P
O	2091	2096	value
O	2097	2101	from
O	2102	2105	the
O	2106	2112	Fisher
O	2113	2118	exact
O	2119	2123	test
O	2124	2127	was
O	2128	2129	<
O	2129	2130	.
O	2130	2133	001
O	2133	2134	,
O	2135	2140	which
O	2141	2148	crossed
O	2149	2152	the
O	2153	2164	superiority
O	2165	2173	boundary
O	2174	2175	(
O	2175	2176	P
O	2177	2178	=
O	2179	2180	.
O	2180	2184	0061
O	2184	2185	)
O	2185	2186	,
O	2187	2190	the
O	2191	2195	data
O	2196	2199	and
O	2200	2206	safety
O	2207	2217	monitoring
O	2218	2223	board
O	2224	2235	recommended
O	2236	2241	study
O	2242	2253	termination
O	2254	2256	on
O	2257	2266	September
O	2267	2269	26
O	2269	2270	,
O	2271	2275	2016
O	2275	2276	.

O	2277	2282	There
O	2283	2287	were
O	2288	2290	no
O	2291	2304	statistically
O	2305	2316	significant
O	2317	2328	differences
O	2329	2331	in
B-outcome	2332	2339	changes
I-outcome	2340	2342	in
I-outcome	2343	2346	any
I-outcome	2347	2349	of
I-outcome	2350	2353	the
I-outcome	2354	2360	scales
I-outcome	2361	2363	of
I-outcome	2364	2371	quality
I-outcome	2372	2374	of
I-outcome	2375	2379	life
O	2380	2384	from
O	2385	2393	baseline
O	2394	2396	to
O	2397	2409	chemotherapy
O	2410	2415	cycle
O	2416	2417	4
O	2418	2423	among
O	2424	2427	the
O	2428	2433	scalp
O	2434	2441	cooling
O	2442	2445	and
O	2446	2453	control
O	2454	2460	groups
O	2460	2461	.

O	2462	2466	Only
B-outcome	2467	2474	adverse
I-outcome	2475	2481	events
O	2482	2489	related
O	2490	2492	to
O	2493	2499	device
O	2500	2503	use
O	2504	2508	were
O	2509	2518	collected
O	2518	2519	;
B-cv-bin-abs	2520	2522	54
O	2523	2530	adverse
O	2531	2537	events
O	2538	2542	were
O	2543	2551	reported
O	2552	2554	in
O	2555	2558	the
O	2559	2566	cooling
O	2567	2572	group
O	2572	2573	,
O	2574	2577	all
O	2578	2584	grades
O	2585	2586	1
O	2587	2590	and
O	2591	2592	2
O	2592	2593	.

O	2594	2599	There
O	2600	2604	were
O	2605	2607	no
O	2608	2615	serious
B-outcome	2616	2623	adverse
I-outcome	2624	2630	device
I-outcome	2631	2637	events
O	2637	2638	.

O	2639	2644	Among
O	2645	2650	women
O	2651	2655	with
O	2656	2661	stage
O	2662	2663	I
O	2664	2666	to
O	2667	2669	II
O	2670	2676	breast
O	2677	2683	cancer
O	2684	2693	receiving
O	2694	2706	chemotherapy
O	2707	2711	with
O	2712	2713	a
O	2714	2720	taxane
O	2720	2721	,
O	2722	2735	anthracycline
O	2735	2736	,
O	2737	2739	or
O	2740	2744	both
O	2744	2745	,
O	2746	2751	those
O	2752	2755	who
O	2756	2765	underwent
O	2766	2771	scalp
O	2772	2779	cooling
O	2780	2784	were
O	2785	2798	significantly
O	2799	2803	more
O	2804	2810	likely
O	2811	2813	to
O	2814	2818	have
O	2819	2823	less
O	2824	2828	than
O	2829	2831	50
O	2831	2832	%
O	2833	2837	hair
O	2838	2842	loss
O	2843	2848	after
O	2849	2852	the
O	2853	2859	fourth
O	2860	2872	chemotherapy
O	2873	2878	cycle
O	2879	2887	compared
O	2888	2892	with
O	2893	2898	those
O	2899	2902	who
O	2903	2911	received
O	2912	2914	no
O	2915	2920	scalp
O	2921	2928	cooling
O	2928	2929	.

O	2930	2937	Further
O	2938	2946	research
O	2947	2949	is
O	2950	2956	needed
O	2957	2959	to
O	2960	2966	assess
O	2967	2973	longer
O	2973	2974	-
O	2974	2978	term
O	2979	2987	efficacy
O	2988	2991	and
O	2992	2999	adverse
O	3000	3007	effects
O	3007	3008	.
O	3009	3023	clinicaltrials
O	3023	3024	.
O	3024	3027	gov
O	3028	3038	Identifier
O	3038	3039	:
O	3040	3051	NCT01986140
O	3051	3052	.
